Tempest Therapeutics, Inc. stock is traded on the Nasdaq Stock Market under the ticker symbol TPST. Tempest Therapeutics, Inc. is in the Biotechnology & Medical Research industry.
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.
Stock Ticker Symbol Lookup
Here you can look up another stock ticker symbol.
Stock Ticker Symbol SCOR
Here is another stock ticker symbol that we have information about!
Contact | Disclaimer | Copyright | Privacy